Story · Medicine & Biotech

Zabopegdutide shows 63% MASH resolution in Phase 2 trial

1 outlet · first reported by Longevity.Technology on

D&D Pharmatech presented final 48-week Phase 2 liver biopsy data for Zabopegdutide at the AASLD meeting in November 2026. According to the company, the treated group achieved 62.5% MASH resolution without worsening fibrosis versus 5.3% for placebo (p<0.001), 50.0% fibrosis improvement without… (Longevity.Technology)

Coverage, in order

  1. Longevity.Technology UK indie study randomized trial
    Zabopegdutide shows 63% MASH resolution in Phase 2 trial

    D&D Pharmatech presented final 48-week Phase 2 liver biopsy data for Zabopegdutide at the AASLD meeting in November 2026. According to the company, the treated group achieved 62.5% MASH resolution without worsening fibrosis versus 5.3% for placebo (p<0.001), 50.0% fibrosis improvement without…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.